Welireg™  (belzutifan)

Welireg™ Is Available From Onco360

WELIREG™ (belzutifan) is a hypoxia-inducible factor inhibitor indicated for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.

Dosage and Administration1

The recommended dose for WELIREG is 120 mg (40 mg tablet x 3) orally once daily.

Dosage Forms and Strengths

WELIREG is available in 40 mg tablets (NDC 0006-5331-01) in 90 count pill bottles.
For full prescribing details visit: Welireg

How to Refer

Limited Distribution Oncology Medications


Oncomed Dba Onco360 or
NPI# 1679618151

VONJO™ (pacritinib) for Myelofibrosis


How to Refer

 1WELIREG prescribing information: Merck & Co., Inc. Accessed 7.21. WELIREG © copyright 2021 Merck Sharp & Dohme Corp., a subsidary of Merck & Co., Inc. All rights reserved